|We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.
Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.
|Date||Title|| || |
|20-Sep-2018||ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer|
|LYON, France and CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first three patients have been enrolled in its pivotal Phase 3 clinical trial, named ‘TRYbeCA1’, evaluating its lead product candidate eryaspase for the treatment of second line metastatic pancreatic cancer.
The TR... || |
|13-Sep-2018||ERYTECH to Attend Upcoming Investor Conferences|
|LYON, France, Sept. 13, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that members of its management team will present and host investor meetings at the following investor conferences in September 2018:
Morgan Stanley Global Healthcare Conference
Attendee: Gil Beyen, Chief Executive Offi... || |
|10-Sep-2018||ERYTECH Reports First Half of 2018 Financial Results and Provides Business Update|
|Conference call and webcast scheduled for Tuesday, September 11th
at 2:30 pm CET/8:30 am EDT
Strategic shift to development of eryaspase for solid tumors confirmed
Phase 3 trial for eryaspase in second line pancreatic cancer initiated and open for patient enrollment
Phase 2 trial in triple-negative breast cancer on track for start of patient enrollment in Q4
Cash position of €165 million ($193 million) as of June 30, 2018
LYON , France and CAMBRIDGE, Mass., Sept. 10, 2018 (... || |
|06-Sep-2018||ERYTECH to Host Second Quarter 2018 Conference Call and Business Update|
|(GLOBE NEWSWIRE via COMTEX) --LYON, France, Sept. 06, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a second quarter 2018 conference call and webcast on Tuesday, September 11, 2018, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights.
The call is accessible via the below te... || |
|11/13/18 2:30 p.m. CET|
|Erytech Pharma Third Quarter 2018 Conference Call and Webcast|
| Receive E-mail Alerts|
|Sign up to receive e-mail alerts whenever Erytech Pharma SA posts new information to the site. Just enter your e-mail address and click Submit.|
ERYTECH Pharma complies with GDPR regulations. For more information about your data, please click here.